Frank Yocca

Company: BioXcel

Job title: Senior Vice President & Chief Scientific Officer

Seminars:

IGALMI: Sublingual Dexmedetomidine for the Acute Treatment of Agitation in Schizophrenia and Bipolar Disorder 11:45 am

Use of AI for identifying and developing a therapeutic for an underserved indication Overview and key decisions/data in the discovery, formulation and development of IGALMI for treating acute agitation Applying a “Land and Expand” strategy for new indications and broadening commercial opportunities for IGALMIRead more

day: Day One